기업 프로필 · Healthcare

Thermo Fisher Scientific Inc

TMO · 미국
거래소
미국
국가 / 지역
USA
상장일
1978년 1월 13일
직원 수
125,000
현재가
$559.53
실시간 · 2026년 7월 27일
베일리 성장 점수
47/100
다소 약함
내재가치 · 3단계 구간 현재가 $559.53 실시간 · 낙관적 내재가치 구간 내 · 상당한 기대가 선반영

종합 밸류에이션 구간 · 보수적 $340–$385 / 적정 $440–$495 / 낙관적 $545–$615. $559.53 기준, 낙관적 내재가치 구간 내 · 상당한 기대가 선반영.

보고서 발행 시 $448.28(2026년 5월 25일)

시가총액US$2126.86억
매출 (TTM)US$463.36억
EBITDAUS$116.66억
순이익률15.04%
ROE13.52%
PER (TTM)30.55
선행 PER23.04
PEG1.89
EPSUS$18.60
배당수익률0.15%
52주 범위US$434.83 – US$642.71
애널리스트 목표주가US$615.12
애널리스트 평가4.4 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

연혁

Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts, with an IPO date of January 13, 1978. Under its "serving science" mission, the company grew through long-term acquisition integration led by CEO Marc Casper, who has held the role since 2009. It now operates through four segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services—and employs about 125,000 people across a portfolio of brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon, and PPD.

업계 내 위치

Thermo Fisher provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services to pharmaceutical and biotech firms, academic and government research institutions, hospitals, clinical labs, and industrial and environmental customers in North America, Europe, Asia-Pacific, and internationally. In 2025 it generated revenue of USD 44.556 billion. Its competitors include Danaher (2025 sales about USD 24.568 billion), Agilent (fiscal 2025 net revenue about USD 6.948 billion), and Waters (2025 net sales about USD 3.165 billion).

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.